Best Warren Buffett Stocks To Buy For 2019


Apple, which already held the crown as the nation’s most-valuable company, made Wall Street history Thursday when it became the first publicly traded U.S. corporation to reach a market value of $1 trillion.

Apple, whose stock is owned by investors ranging from billionaire Warren Buffett to mutual fund giant Vanguard to millions of working Americans through funds owned in their 401(k)s, passed the milestone days after reporting another stellar quarter, highlighted by a jump in revenue to $53.3 billion and the sale of 41.3 million iPhones.

The iPhone maker broke the $1 trillion barrier when its stock briefly hit the magic share price of $207.05, according to Nanex, which supplies market data to the financial industry. Online brokerage TD Ameritrade said the history-making trade occurred at 11:48 a.m. ET.

Best Warren Buffett Stocks To Buy For 2019: First Horizon National Corporation(FHN)


Advisors’ Opinion:

  • [By Logan Wallace]

    First Horizon National (NYSE:FHN) will be posting its quarterly earnings results before the market opens on Thursday, July 12th.

    First Horizon National (NYSE:FHN) last posted its earnings results on Friday, April 13th. The financial services provider reported $0.34 EPS for the quarter, topping the Zacks’ consensus estimate of $0.30 by $0.04. First Horizon National had a return on equity of 9.37% and a net margin of 12.30%. The business had revenue of $437.20 million for the quarter, compared to analysts’ expectations of $438.60 million. During the same quarter in the previous year, the firm earned $0.23 earnings per share. The business’s revenue was up 42.6% compared to the same quarter last year. On average, analysts expect First Horizon National to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

  • [By Joseph Griffin]

    Cadence Capital Management LLC boosted its holdings in First Horizon National Corp (NYSE:FHN) by 173.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,515 shares of the financial services provider’s stock after buying an additional 19,357 shares during the quarter. Cadence Capital Management LLC’s holdings in First Horizon National were worth $544,000 at the end of the most recent reporting period.

  • [By Logan Wallace]

    Brown Advisory Inc. grew its holdings in First Horizon National Corp (NYSE:FHN) by 117.2% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 65,240 shares of the financial services provider’s stock after acquiring an additional 35,197 shares during the quarter. Brown Advisory Inc.’s holdings in First Horizon National were worth $1,164,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By ]

    In an “Executive Decision” segment, Cramer sat down with Bryan Jordan, chairman, president and CEO of First Horizon National (FHN) , the Tennessee-based regional bank that just posted a three-cents-a-share earnings beat with net interest margins up 52 basis points.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on First Horizon National (FHN)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Best Warren Buffett Stocks To Buy For 2019: GlaxoSmithKline PLC(GSK)

Advisors’ Opinion:

  • [By Keith Speights]

    It’s been a very different year so far for two big pharma stocks: One’s hot and one’s not. Things are going great for GlaxoSmithKline plc (NYSE:GSK) as its share price is up around 15% year to date. But for Johnson & Johnson (NYSE:JNJ), it’s a different story. J&J stock is down more than 10% in 2018.

  • [By George Budwell]

    After a prolonged downturn, British pharma goliath GlaxoSmithKline (NYSE:GSK) has finally started to recapture the imagination of Wall Street. The overwhelming majority of analysts covering the stock, for instance, have a favorable rating on Glaxo’s shares right now, and large institutional investors have been slowly upping their positions in this downtrodden big pharma equity in recent quarters.    

  • [By Chris Lange]

    GlaxoSmithKline PLC (NYSE: GSK) has a meeting with the FDA’s Pulmonary-Allergy Drugs Advisory Committee scheduled for July 25. The meeting is in regards to the firm’s supplementary Biologics License Agreement (sBLA) for its chronic obstructive pulmonary disease (COPD) treatment, mepolizumab.

  • [By ]

    HSBC’s top stocks list is mostly dominated by large-cap plays that happen to pay attractive dividend yields. More importantly, the stocks already have a decent amount of momentum behind them: the average one-month performance is +5.5%. 

    Baker Hughes (BHGE) Tiffany & Co. (TIF) The Mosaic Company (MOS) Deutsche Telekom Schneider Electric Adidas (ADDYY) Unicredit  CRH (CRH) Luftansa  GlaxosmithKline (GSK) Associated British Foods   Fresnillo China Construction Bank China Overseas Land & Inv. Geely Automobile Holdings CRCC China Resources Beer Samsung Electronic Sasol Adani Ports and SEZ

  • [By Keith Speights]

    GlaxoSmithKline (GSK), like Teva, lost ground last year, with its stock declining by nearly 8%. So far in 2018, though, GSK’s share price is up more than 12% — trouncing the major indexes.

Best Warren Buffett Stocks To Buy For 2019: TransAct Technologies Incorporated(TACT)

Advisors’ Opinion:

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on TransAct Technologies (TACT)


    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    Logitech (NASDAQ: LOGI) and TransAct Technologies (NASDAQ:TACT) are both computer and technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on TransAct Technologies (TACT)


    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Ethan Ryder]

    TransAct Technologies Incorporated (NASDAQ:TACT) Chairman Bart C. Shuldman sold 1,272 shares of TransAct Technologies stock in a transaction dated Tuesday, September 4th. The stock was sold at an average price of $14.35, for a total value of $18,253.20. Following the completion of the transaction, the chairman now directly owns 18,205 shares in the company, valued at approximately $261,241.75. The sale was disclosed in a document filed with the SEC, which is available at this link.

Best Warren Buffett Stocks To Buy For 2019: TESARO, Inc.(TSRO)


Advisors’ Opinion:

  • [By Chris Lange]

    Buy-dip on several “Potential Blockbusters” Aimmune Therapeutics, Inc. (NASDAQ: AIMT), Audentes Therapeutics, Inc. (NASDAQ: BOLD), AveXis, Inc. (NASDAQ: AVXS), Bluebird Bio, Inc. (NASDAQ: BLUE), Esperion Therapeutics, Inc. (NASDAQ: ESPR), and Sage Therapeutics, Inc. (NASDAQ: SAGE) are buy-dip candidates given their bullish trends and favorable technical patterns. Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT), Prothena Corp. PLC (NASDAQ: PRTA), Tesaro, Inc. (NASDAQ: TSRO) and Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) have bearish set-ups. Heron Therapeutics, Inc. (NASDAQ: HRTX) is bigger picture bullish, but may correct further on a move below $19.55. Clovis Oncology, Inc. (NASDAQ: CLVS) has bearish set-up and bulls need to push above $69 to invalidate.

  • [By Brian Orelli]

    The phase 2 TOPACIO/Keynote-162 trial tests Tesaro’s (NASDAQ:TSRO) poly (ADP-ribose) polymerase (PARP) inhibitor, Zejula, with Keytruda. On Sunday, outcomes for patients with recurrent ovarian cancer will be presented, as Tesaro and Merck look to build on earlier promising results. Then on Monday, the duo will present data testing the combination in patients with metastatic triple-negative breast cancer as Tesaro looks to expand the market for Zejula.

  • [By Cory Renauer]

    All of these biotech stocks have been battered for different reasons, and bouncing back will be a lot easier for some than for others. 


    Company (Symbol) One-Month Loss  Market Capitalization
    Idera Pharmaceuticals (NASDAQ:IDRA) (35%) $199.7 million
    Spark Therapeutics (NASDAQ:ONCE) (38%) $2.16 billion
    Tesaro (NASDAQ:TSRO) (40%) $1.49 billion

    Here’s what needs to happen if these stocks are going to mount a comeback.

  • [By Todd Campbell]

    Tesaro, Inc. (NASDAQ:TSRO) shares are rallying this week on rumors it’s an acquisition target. The company, which markets two cancer drugs, recently increased its sales guidance because of growing demand. Given that shares are trading at a steep discount to where they were last year, it could be the perfect time for a suitor to come knocking. Here’s what investors should know about this company and why it could be attractive to a buyer.

  • [By Paul Ausick]

    Tesaro Inc. (NASDAQ: TSRO) traded down about 10% Tuesday and posted a new 52-week low of $74.57 after Friday at $82.87. The 52-week high is $192.94. Volume was about 2 million, more than double the daily average of around 870,000 million shares. The maker of cancer therapeutics had no specific news.

Leave a Reply

Your email address will not be published.